Jeffrey Meckler - Indaptus Therapeutics CEO Director

INDP Stock  USD 2.25  0.03  1.35%   


Jeffrey Meckler is CEO Director of Indaptus Therapeutics
Age 57
Address Three Columbus Circle, New York, NY, United States, 10019
Phone646 427 2727

Jeffrey Meckler Latest Insider Activity

Tracking and analyzing the buying and selling activities of Jeffrey Meckler against Indaptus Therapeutics stock is an integral part of due diligence when investing in Indaptus Therapeutics. Jeffrey Meckler insider activity provides valuable insight into whether Indaptus Therapeutics is net buyers or sellers over its current business cycle. Note, Indaptus Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Indaptus Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Indaptus Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.5817) % which means that it has lost $0.5817 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9806) %, meaning that it created substantial loss on money invested by shareholders. Indaptus Therapeutics' management efficiency ratios could be used to measure how well Indaptus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 07/13/2024, Return On Tangible Assets is likely to drop to -1.09. In addition to that, Return On Capital Employed is likely to grow to -1.28. At this time, Indaptus Therapeutics' Total Current Liabilities is relatively stable compared to the past year. As of 07/13/2024, Liabilities And Stockholders Equity is likely to grow to about 23.5 M, while Non Current Liabilities Total is likely to drop slightly above 69.7 K.
Indaptus Therapeutics currently holds 175.05 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Indaptus Therapeutics has a current ratio of 9.0, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Indaptus Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives


Daniel FinkeCVS Health Corp
Courtney DeanCaterpillar
Pasquale FioreAlcoa Corp
Vanessa BroadhurstJohnson Johnson
William HaitJohnson Johnson
Michael AngelakisExxon Mobil Corp
Bradley GaytonThe Coca Cola
Laurie HavanecCVS Health Corp
Yan LuoXiaomi Corp
Sai LamXiaomi Corp
Robert DeckerJohnson Johnson
G MarvelCaterpillar
Nadja WestJohnson Johnson
Isabella GorenGE Aerospace
Mathai MammenJohnson Johnson
William RobinsonGE Aerospace
Tammi JonesAlcoa Corp
Tomislav MihaljevicGE Aerospace
Kathy LovelessThe Coca Cola
Raymond JoabarAmerican Express
D DavisJohnson Johnson
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York. Indaptus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people. Indaptus Therapeutics (INDP) is traded on NASDAQ Exchange in USA. It is located in Three Columbus Circle, New York, NY, United States, 10019 and employs 7 people. Indaptus Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Indaptus Therapeutics Leadership Team

Elected by the shareholders, the Indaptus Therapeutics' board of directors comprises two types of representatives: Indaptus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Indaptus. The board's role is to monitor Indaptus Therapeutics' management team and ensure that shareholders' interests are well served. Indaptus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Indaptus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
MD MBA, Chief Officer
Jeffrey Meckler, CEO Director
Nir Sassi, Secretary CFO
Walt Esq, Chief Officer
Michael Newman, Chief Founder
Boyan MD, Chief Officer

Indaptus Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Indaptus Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Indaptus Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Indaptus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Indaptus Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Indaptus Stock

  0.53EWTX Edgewise TherapeuticsPairCorr
  0.31GOSS Gossamer BioPairCorr
The ability to find closely correlated positions to Indaptus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Indaptus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Indaptus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Indaptus Therapeutics to buy it.
The correlation of Indaptus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Indaptus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Indaptus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Indaptus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Indaptus Stock Analysis

When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.